{
    "ticker": "FNCH",
    "name": "Finch Therapeutics Group, Inc.",
    "description": "Finch Therapeutics Group, Inc. is a clinical-stage biotechnology company focused on developing novel microbiome therapeutics to treat a variety of diseases. Founded in 2017, Finch leverages its proprietary microbiome platform to harness the potential of the human microbiome in transforming patient outcomes. The company aims to address conditions that are poorly managed with existing therapies, including recurrent Clostridium difficile infection and inflammatory bowel diseases. Finch\u2019s lead product candidate, CP101, is an oral microbiome therapy designed to restore a healthy gut microbiome in patients suffering from recurrent C. diff infections. The company is committed to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions. Finch believes that understanding and manipulating the microbiome can lead to breakthroughs in treating a range of diseases, including metabolic, gastrointestinal, and autoimmune disorders. With a strong scientific foundation and a dedicated team of experts, Finch Therapeutics is at the forefront of microbiome innovation, striving to improve the lives of patients through groundbreaking therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Somerville, Massachusetts, USA",
    "founded": "2017",
    "website": "https://www.finchthera.com",
    "ceo": "Mark Smith",
    "social_media": {
        "twitter": "https://twitter.com/FinchThera",
        "linkedin": "https://www.linkedin.com/company/finch-therapeutics/"
    },
    "investor_relations": "https://ir.finchthera.com",
    "key_executives": [
        {
            "name": "Mark Smith",
            "position": "CEO"
        },
        {
            "name": "Darin D. Dorsey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Microbiome Therapeutics",
            "products": [
                "CP101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Finch Therapeutics Group, Inc. | Innovating Microbiome-Based Therapies",
        "meta_description": "Explore Finch Therapeutics Group, Inc., a leader in microbiome therapeutics aiming to transform patient care through innovative products targeting various diseases.",
        "keywords": [
            "Finch Therapeutics",
            "Microbiome",
            "Biotechnology",
            "Clostridium difficile",
            "CP101",
            "Health Innovation"
        ]
    },
    "faq": [
        {
            "question": "What is Finch Therapeutics known for?",
            "answer": "Finch Therapeutics is known for developing microbiome-based therapies to treat diseases such as recurrent C. difficile infection."
        },
        {
            "question": "Who is the CEO of Finch Therapeutics?",
            "answer": "Mark Smith is the CEO of Finch Therapeutics Group, Inc."
        },
        {
            "question": "Where is Finch Therapeutics headquartered?",
            "answer": "Finch Therapeutics is headquartered in Somerville, Massachusetts, USA."
        },
        {
            "question": "What is Finch's lead product?",
            "answer": "Finch's lead product candidate is CP101, an oral microbiome therapy for recurrent C. difficile infection."
        },
        {
            "question": "When was Finch Therapeutics founded?",
            "answer": "Finch Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "CRSP",
        "SGMO",
        "EDIT",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}